ITG-HM4V6B-100μg / 询价
ITG-HM4V6B-500μg / 询价
ITG-HM4V6B-500μgx2 / 询价
Biotinylated Human Integrin alpha V beta 6 (ITGAV&ITGB6) Heterodimer Protein
Recombinant Biotinylated Human Integrin alpha V beta 6 (ITGAV&ITGB6) Heterodimer Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus.It contains Phe31-Val992(ITGAV) acidic tail & Gly22-Asn707(ITGB6) basic tail [Accession | P06756-1(ITGAV)&P18564-1(ITGB6)].
The protein has a predicted MW of 114 kDa (ITGAV)&79.1 kDa (ITGB6). Due to glycosylation, the protein migrates to 90-150 kDa based on Bis-Tris PAGE result.
> 95% as determined by Bis-Tris PAGE
> 95% as determined by HPLC
Less than 1EU per μg by the LAL method.
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
-20 to -80°C for 12 months as supplied from date of receipt.
-80°C for 3 months after reconstitution.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Biotinylated Human ITGAV&ITGB6 on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
The purity of Biotinylated Human ITGAV&ITGB6 is greater than 95% as determined by SEC-HPLC.
Immobilized Human Latent TGF beta 1, His Tag at 2μg/ml (100μl/well) on the plate. Dose response curve for Biotinylated Human ITGAV&ITGB6, His Tag with the EC50 of 2.2μg/ml determined by ELISA.
ITGAV&ITGB6 is a receptor for fibronectin and cytotactin. It recognizes the sequence R-G-D in its ligands. Internalisation of integrin alpha-V/beta-6 via clathrin-mediated endocytosis promotes carcinoma cell invasion. ITGAV&ITGB6 acts as a receptor for fibrillin-1 (FBN1) and mediates R-G-D-dependent cell adhesion to FBN1.
αVβ6; Integrin alpha V beta 6; ITGAV&ITGB6;Integrin alpha V β 6
(1) Li J, Xu YH, Lu Y, Ma XP, Chen P, Luo SW, Jia ZG, Liu Y, Guo Y. Identifying differentially expressed genes and small molecule drugs for prostate cancer by a bioinformatics strategy. Asian Pac J Cancer Prev. 2013;14(9):5281-6. doi: 10.7314/apjcp.2013.14.9.5281. PMID: 24175814.
